Health Care • Biotechnology: Pharmaceutical Preparations
$67.18 ▲ +1.25
(+1.90%)
MKT CAP: $38.63B • VOL: 4.66M
52W L $36 52W H $68
RPRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.38B | $2.26B | $2.35B |
| YoY Revenue Growth % | +5.1% | -3.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.56B | $1.29B | $1.49B |
| Operating Margin % | 65.6% | 57.1% | 63.4% |
| Net Income (GAAP) | $770.9M | $859.0M | $1.13B |
| EBITDA (Normalized) | $1.65B | $1.37B | $1.58B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.49B | $2.77B | $2.99B |
| Capital Expenditures (CapEx) | $107.0M | $101.9M | $106.0M |
| Free Cash Flow (FCF) | $2.38B | $2.67B | $2.88B |
| FCF Margin % | 100.2% | 117.8% | 122.4% |
| Return on Invested Capital (ROIC %) | 7.0% | 6.4% | 9.4% |
| Cash & Short-Term Equivalents | $618.7M | $929.0M | — |
| Total Debt (Short + Long Term) | $8.57B | $6.61B | $4.88B |
| Total Stockholders' Equity | $9.71B | $10.34B | $10.01B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RPRX.